https://firstwordpharma.com/story/5705118

"The drug was being developed under a partnership struck with Arena Pharmaceuticals for palmoplantar pustulosis and other potential neutrophil-mediated diseases such as hidradenitis suppurativa and inflammatory bowel disease. The deal came with a $60-million upfront payment plus an equity investment of $10 million. Arena has since been acquired by Pfizer."





https://www.businesswire.com/news/home/20210727006087/en/Arena-Pharmaceuticals-and-Aristea-Therapeutics-Est
ablish-Collaboration-for-Development-of-RIST4721-for-Treatment-of-Serious-Immune-Mediated-Inflammatory-Diseases